全乳切除术后放疗中bolus的使用对局部控制的影响
该研究分析了1887例无皮肤受累的浸润性乳腺癌患者,在接受全乳切除术后三维适形放疗时使用或不使用bolus对局部复发(LR)、局部区域复发(LRR)和乳腺癌死亡率(BCM)的影响。结果显示,使用bolus未改善LR或BCM,且10年LR发生率均较低。结论认为,对于接受全身治疗且无皮肤受累的患者,不应常规使用bolus。
要点
- bolus组10年LR为1.9%,无bolus组为0.9%,差异无统计学意义。
- 多因素分析显示bolus使用与更好的LR或BCM无关。
- 对于无皮肤受累且接受全身治疗的患者,不建议常规使用bolus。
核心结论
- 对于全乳切除术后接受放疗和现代全身治疗的无皮肤受累患者,使用bolus未降低局部复发或乳腺癌死亡率,且增加皮肤毒性,不应常规使用。
研究设计与样本
- 回顾性队列研究,纳入1887例新诊断浸润性乳腺癌无皮肤受累(pT1-4a,任何N,M0)接受辅助或新辅助放疗的患者,比较bolus组(1569例)与无bolus组(318例)的结局。
主要发现
- bolus组与无bolus组的10年LR分别为1.9%(95%CI 1.3-2.7)和0.9%(95%CI 0.3-2.6)。
- bolus组与无bolus组的10年LRR分别为3.1%(95%CI 2.3-4.0)和3.2%(95%CI 1.6-5.5)。
- bolus组与无bolus组的10年BCM分别为19.4%(95%CI 17.3-21.6)和18.3%(95%CI 13.9-23.2)。
- 多因素分析中,bolus使用与LR无关(HR=1.4,95%CI 0.3-6.4),与BCM无关(HR=0.8,95%CI 0.5-1.2)。
关键数值与推荐
- bolus在重建患者中的使用比例为51%(281/550),在非重建患者中为96%(1288/1337)。
- 98%的患者接受了全身治疗。
临床怎么用
- 对于无皮肤受累且接受全身治疗的全乳切除术后放疗患者,可考虑省略bolus以降低皮肤毒性。
局限性
- 研究为回顾性设计,bolus组与非bolus组样本量差异较大,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Bolus use during postmastectomy radiation therapy doubles the risk of grade 2 and 3 skin toxicity. Despite its unknown benefit, bolus is often prescribed during postmastectomy radiation therapy for patients without skin involvement. METHODS AND MATERIALS: For women with breast cancer receiving photon 3-dimensional conformal radiation therapy, bolus was used routinely for chest walls but was omitted for breast reconstructions by about half of radiation oncologists from 2007 to 2011. Eligible patients had newly diagnosed invasive breast cancers without skin involvement (pT1-4a, any-N, M0) treated with adjuvant or neoadjuvant radiation therapy. For the bolus and no-bolus groups, we compared the cumulative incidence of local recurrence (LR) and locoregional recurrence (LRR) with distant recurrence and death as competing risks and breast cancer mortality (BCM). Multivariable analysis of LR and BCM included stage, subtype, lymphovascular invasion, grade, margin status, beam energy, bolus use, hormone therapy, chemotherapy, and reconstruction. RESULTS: Systemic therapy was used for 98% of the 1887 patients. The bolus group had 1569 patients and the no-bolus group had 318 patients. Bolus was used in 51% (281/550) of patients treated with reconstruction and 96% (1288/1337) of patients treated without reconstruction. The 10-year outcomes (95% confidence interval) in patients treated with and without bolus were, respectively: LR 1.9% (1.3-2.7) versus 0.9% (0.3-2.6), LRR 3.1% (2.3-4.0) versus 3.2% (1.6-5.5), and BCM 19.4% (17.3-21.6) versus 18.3% (13.9-23.2). On multivariable analysis, bolus use was not associated with better LR (hazard ratio = 1.4 [0.3-6.4]) or BCM (hazard ratio = 0.8 [0.5-1.2]). CONCLUSIONS: For patients treated with mastectomy, radiation therapy, and modern systemic therapy, the cumulative incidence of LR was low, with or without bolus. Because bolus use increases toxicity and does not reduce LR or BCM, it should no longer be used routinely for patients without skin involvement who receive systemic therapy.
引用
- Nichol A, Narinesingh D, Raman S, et al. The Effect of Bolus on Local Control for Patients Treated With Mastectomy and Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021. PMID: 33485893. doi:10.1016/j.ijrobp.2021.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。